

# ABELCET

---

## Products Affected

- ABELCET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Subject to Part B vs Part D determination. Failure or clinically significant adverse effects to the formulary alternative: conventional Amphotericin B.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ABILIFY MAINTENA

---

**Products Affected**

- ABILIFY MAINTENA  
INTRAMUSCULAR  
SUSPENSION,EXTENDED REL  
RECON 300 MG, 400 MG
- ABILIFY MAINTENA  
INTRAMUSCULAR  
SUSPENSION,EXTENDED REL  
SYRING

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented history of receiving oral aripiprazole without any clinically significant side effects.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: Invega Sustenna, Invega Trinza or Risperdal Consta.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ACITRETIN

---

## Products Affected

- *acitretin*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Dermatologist
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to two of the formulary alternatives: calcipotriene, clobetasol, cyclosporine, fluocinonide, methotrexate, or Tazorac.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# ACTIMMUNE

---

## Products Affected

- ACTIMMUNE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Hematologist, Infectious Disease specialist, Oncologist, Orthopedist, Rheumatologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ADEFOVIR

---

## Products Affected

- *adefovir*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Gastroenterologist, Hepatologist, Infectious Disease specialist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ADHD

## Products Affected

- *dexmethylphenidate oral tablet*
- *methylphenidate hcl oral capsule, er biphasic 30-70*
- *methylphenidate hcl oral capsule, er biphasic 50-50*
- *methylphenidate hcl oral solution*
- *methylphenidate hcl oral tablet*
- *methylphenidate hcl oral tablet extended release*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AIMOVIG

---

## Products Affected

- AIMOVIG AUTOINJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurologist, Headache Specialist, Pain Specialist
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to one of the formulary alternatives: divalproex, valproic acid, or topiramate and failure or clinically significant adverse effects to one of the formulary alternatives: metoprolol, timolol, propranolol.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# ALOSETRON

---

## Products Affected

- *alosetron*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Irritable bowel syndrome with diarrhea: Failure or clinically significant adverse effects to the formulary alternative: loperamide.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# AMBISOME

---

## Products Affected

- AMBISOME

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Subject to Part B vs Part D determination. Failure or clinically significant adverse effects to the formulary alternative: conventional Amphotericin B.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AMITRIPTYLINE

---

## Products Affected

- *amitriptyline*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Depression: Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AMOXAPINE

---

## Products Affected

- *amoxapine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# AMPHOTERICIN B

---

## Products Affected

- *amphotericin b*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Subject to Part B vs Part D determination.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# ANTICONVULSANTS 1

## Products Affected

- APTIOM ORAL TABLET 200 MG, 400 MG, 600 MG, 800 MG
- BRIVIACT ORAL SOLUTION
- BRIVIACT ORAL TABLET 10 MG, 100 MG, 25 MG, 50 MG, 75 MG
- EPIDIOLEX
- FYCOMPA ORAL SUSPENSION
- FYCOMPA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurologist
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to one of the formulary alternatives: carbamazepine, clonazepam, divalproex, ethosuximide, felbamate, gabapentin, lamotrigine, levetiracetam, lorazepam, oxcarbazepine, phenytoin, tiagabine, topiramate, valproic acid or zonisamide.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

## ANTICONVULSANTS 2

### Products Affected

- *clobazam oral suspension*
- *clobazam oral tablet*
- DIACOMIT
- FINTEPLA
- VIMPAT ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Clobazam, Fenfluramine, or Stiripentol: Must be used as adjunctive treatment of seizure. Lacosamide: For partial seizure: Failure or clinically significant adverse effects to two of the following: carbamazepine, divalproex, felbamate, gabapentin, levetiracetam, oxcarbazepine, phenytoin, tiagabine, topiramate, valproic acid or zonisamide. For tonic-clonic seizure: Failure or clinically significant adverse effects to two of the following: lamotrigine, levetiracetam, phenytoin, or topiramate.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ANTINEOPLASTIC

---

## Products Affected

- *abiraterone oral tablet 250 mg, 500 mg*
- AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 2 MG
- ALECENSA
- ALUNBRIG
- AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG
- BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG
- BESREMI
- BOSULIF
- BRAFTOVI ORAL CAPSULE 75 MG
- BRUKINSA
- CABOMETYX
- CALQUENCE
- CALQUENCE (ACALABRUTINIB MAL)
- CAPRELSA
- COMETRIQ
- COPIKTRA
- COTELLIC
- DAURISMO ORAL TABLET 100 MG, 25 MG
- ERIVEDGE
- ERLEADA
- *erlotinib oral tablet 100 mg, 150 mg, 25 mg*
- *everolimus (antineoplastic) oral tablet*
- *everolimus (antineoplastic) oral tablet for suspension 3 mg, 5 mg*
- EXKIVITY
- FOTIVDA
- GAVRETO
- GILOTRIF
- GLEOSTINE
- IBRANCE
- ICLUSIG ORAL TABLET 10 MG, 15 MG, 30 MG, 45 MG
- IDHIFA
- *imatinib oral tablet 100 mg, 400 mg*
- IMBRUVICA ORAL CAPSULE 140 MG, 70 MG
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG, 560 MG
- INLYTA ORAL TABLET 1 MG, 5 MG
- INQOVI
- INREBIC
- IRESSA
- JAKAFI
- KISQALI FEMARA CO-PACK
- KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3)
- KOSELUGO ORAL CAPSULE 10 MG, 25 MG
- KRAZATI
- *lapatinib*
- *lenalidomide*
- LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1), 12 MG/DAY (4 MG X 3), 14 MG/DAY(10 MG X 1-4 MG X 1), 18 MG/DAY (10 MG X 1-4 MG X2), 20 MG/DAY (10 MG X 2), 24 MG/DAY(10 MG X 2-4 MG X 1), 4 MG, 8 MG/DAY (4 MG X 2)
- LONSURF
- LORBRENA ORAL TABLET 100 MG, 25 MG
- LUMAKRAS
- LYNPARZA
- LYTGABI
- MATULANE
- MEKINIST ORAL TABLET 0.5 MG, 2 MG
- MEKTOVI
- NERLYNX
- NEXAVAR
- NINLARO
- NUBEQA
- ODOMZO
- ONUREG
- ORGOVYX
- PANRETIN

- PEMAZYRE
- PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2)
- POMALYST
- PURIXAN
- QINLOCK
- RETEVMO ORAL CAPSULE 40 MG, 80 MG
- REVLIMID
- REZLIDHIA
- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG
- RUBRACA
- RYDAPT
- SCEMBLIX ORAL TABLET 20 MG, 40 MG
- *sorafenib*
- SPRYCEL ORAL TABLET 100 MG, 140 MG, 20 MG, 50 MG, 70 MG, 80 MG
- STIVARGA
- *sunitinib*
- SUTENT
- SYNRIBO
- TABLOID
- TABRECTA
- TAFINLAR
- TAGRISSO
- TALZENNA ORAL CAPSULE 0.25 MG, 0.5 MG, 0.75 MG, 1 MG
- TASIGNA
- TAZVERIK
- TEPMETKO
- THALOMID
- TIBSOVO
- TRUSELTIQ ORAL CAPSULE 100 MG/DAY (100 MG X 1), 125 MG/DAY(100 MG X1-25MG X1), 50 MG/DAY (25 MG X 2), 75 MG/DAY (25 MG X 3)
- TUKYSA ORAL TABLET 150 MG, 50 MG
- TURALIO ORAL CAPSULE 125 MG, 200 MG
- VENCLEXTA
- VENCLEXTA STARTING PACK
- VERZENIO
- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION
- VIZIMPRO
- VONJO
- VOTRIENT
- WELIREG
- XALKORI
- XERMELO
- XOSPATA
- XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (40 MG X 1), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80MG TWICE WEEK (160 MG/WEEK)
- XTANDI
- YONSA
- ZEJULA
- ZELBORAF
- ZOLINZA
- ZYDELIG
- ZYKADIA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# APOKYN

---

## Products Affected

- APOKYN
- *apomorphine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to two of the formulary alternatives: antiparkinson drugs such as amantadine, bromocriptine, carbidopa/levodopa, entacapone, pramipexole, ropinirole, or selegiline.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# APREPITANT

---

## Products Affected

- *aprepitant*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months.
Other Criteria	Subject to Part B vs Part D determination. Failure or clinically significant adverse effects to one of the formulary 5-HT3 antagonist alternatives: ondansetron or granisetron except when the member is on any chemotherapy.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# ARCALYST

---

## Products Affected

- ARCALYST

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Concurrently taking any tumor necrosis factor (TNF)-blocking agents such as Enbrel, Humira, or Remicade.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ARIPIPAZOLE

## Products Affected

- *aripiprazole oral solution*
- *aripiprazole oral tablet, disintegrating*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of difficulty or inability to swallow or failure or clinically significant adverse effects to the formulary alternative: oral aripiprazole.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ARMODAFINIL

---

## Products Affected

- *armodafinil*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Narcolepsy: Failure or clinically significant adverse effects to all of the formulary alternatives: dextroamphetamine and methylphenidate.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ATOVAQUONE

---

## Products Affected

- *atovaquone*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Pneumocystic pneumonia: Failure or clinically significant adverse effects to the formulary alternative: trimethoprim/sulfamethoxazole.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AUBAGIO

---

## Products Affected

- AUBAGIO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# AUSTEDO

---

## Products Affected

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Concurrent use with an MAOI. Untreated or inadequately-treated depression, or current suicidality in patients with Huntington disease.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist, Psychiatrist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Chorea (Huntington's Disease): Failure or clinically significant adverse effects to the formulary alternative: tetrabenazine. Reauthorization only: Documentation of positive response to medication therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AUVELITY

---

## Products Affected

- AUVELITY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Depression: Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CASPOFUNGIN

---

## Products Affected

- *casposfungin*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CLOMIPRAMINE

---

## Products Affected

- *clomipramine*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: fluoxetine, fluvoxamine, paroxetine, or sertraline.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CLOZAPINE

## Products Affected

- *clozapine oral tablet, disintegrating 100 mg, 12.5 mg, 150 mg, 200 mg, 25 mg*
- VERSACLOZ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of difficulty or inability to swallow or failure or clinically significant adverse effects to the formulary alternative: oral clozapine.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Psychiatrist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CONSTIPATION AGENTS

## Products Affected

- MOVANTIK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to one of the formulary alternatives: lactulose or polyethylene glycol.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# CORLANOR

## Products Affected

- CORLANOR ORAL SOLUTION
- CORLANOR ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Heart failure in adult patients: Documented New York Association (NYHA) class II to IV heart failure with an ejection fraction of less than or equal to 35% and sinus rhythm with a resting heart rate greater than or equal to 70 beats per minute (bpm). Documentation that patient is on maximally tolerated dose of beta blocker or has a history of a documented intolerance, contraindication or a hypersensitivity to beta blocker. Documented concurrent use with an ACE inhibitor or ARB, unless both are not tolerated or contraindicated. Heart failure in pediatric patients: Documented NYHA/Ross class II to IV heart failure with an ejection fraction of less than or equal to 45% and sinus rhythm with a resting heart rate greater than or equal to 105 bpm in the age subset 6-12 months, greater than or equal to 95 bpm in the age subset 1-3 years, greater than or equal to 75 bpm in the age subset 3-5 years, greater than or equal to 70 bpm in the age subset 5-18 years
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Cardiologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# COSENTYX

## Products Affected

- COSENTYX (2 SYRINGES)
- COSENTYX PEN (2 PENS)
- COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Plaque psoriasis: documentation of psoriasis of greater than 3% BSA or affecting crucial body areas such as hands, feet, face or genitals.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Dermatologist, Rheumatologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Ankylosing spondylitis: For adults, failure or clinically significant adverse effects to both of the formulary alternatives: Enbrel and Humira. Psoriatic arthritis: For adults, failure or clinically significant adverse effects to both of the formulary alternatives: Enbrel and Humira. Plaque Psoriasis: For adults, failure or clinically significant adverse effects to one of the formulary alternatives: Humira, Enbrel, or Skyrizi. Non-radiographic Axial Spondyloarthritis: Failure or clinically significant adverse effects to a non-steroidal anti-inflammatory drug (NSAID) or has an intolerance or contraindication to NSAID.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# CYCLOBENZAPRINE

## Products Affected

- *cyclobenzaprine oral tablet 10 mg, 5 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Documentation explaining specific benefit established with the medication, and how that benefit outweighs the potential risk
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DALFAMPRIDINE

---

## Products Affected

- *dalfampridine*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Moderate or severe renal impairment (CrCL 50 mL/min or less).
<b>Required Medical Information</b>	Concurrently on a disease-modifying agent for multiple sclerosis. Documentation of difficulty walking (such as timed 25-foot walk test: Patient must be able to walk 25 feet within 8-45 sec). Reauthorization only: Documentation of positive response to medication therapy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DALIRESP

---

## Products Affected

- DALIRESP
- *roflumilast*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Liver impairment, moderate to severe (Child-Pugh B or C).
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: either Wixela or Fluticasone/Salmeterol, Anoro Ellipta, Serevent, Spiriva or Tudorza.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DEFERASIROX

---

## Products Affected

- *deferasirox oral tablet, dispersible*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematologist
Coverage Duration	Until the end of calendar year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# DESIPRAMINE

---

## Products Affected

- *desipramine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Depression: Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# DIAZEPAM SOLUTION

## Products Affected

- *diazepam intensol*
- *diazepam oral solution 5 mg/5 ml (1 mg/ml)*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of difficulty or inability to swallow.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DIMETHYL FUMARATE

---

## Products Affected

- *dimethyl fumarate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurologist
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to all of the formulary alternatives: Aubagio and glatiramer.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# DISOPYRAMIDE

## Products Affected

- *disopyramide phosphate oral capsule*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: acebutolol, amiodarone, flecainide, mexiletine, propafenone, quinidine, or sotalol.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# DOXEPIN

## Products Affected

- *doxepin oral capsule*
- *doxepin oral concentrate*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	For the average daily dose of doxepin that is greater than 6 mg: Anxiety: Failure or clinically significant adverse effects to two of the formulary alternatives: buspirone, duloxetine, escitalopram, or venlafaxine. Depression: Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DRIZALMA

---

## Products Affected

- DRIZALMA SPRINKLE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of difficulty or inability to swallow an intact capsule or failure or clinically significant adverse effects to the formulary alternative: duloxetine.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DRONABINOL

## Products Affected

- *dronabinol*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Chemotherapy-induced nausea and vomiting: Failure or clinically significant adverse effects to two of the formulary alternatives: chlorpromazine, granisetron, metoclopramide, ondansetron, or prochlorperazine.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# DROXIDOPA

---

## Products Affected

- *droxidopa*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ELIGARD

---

## Products Affected

- ELIGARD
- ELIGARD (3 MONTH)
- ELIGARD (4 MONTH)
- ELIGARD (6 MONTH)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncologist, Urologist
Coverage Duration	Until the end of calendar year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# EMSAM

---

## Products Affected

- EMSAM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Concomitant use with other serotonergic drugs (i.e. SSRIs, SNRIs, TCAs)
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to all of the formulary alternatives: phenelzine and tranylcypromine.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ENBREL

## Products Affected

- ENBREL
- ENBREL MINI
- ENBREL SURECLICK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Plaque psoriasis: documentation of psoriasis of greater than 5% BSA or affecting crucial body areas such as hands, feet, face or genitals.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Dermatologist, Rheumatologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Rheumatoid Arthritis: Failure or clinically significant adverse effects to one of the formulary alternatives: azathioprine, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine. Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate. Ankylosing spondylitis: Failure or clinically significant adverse effects to one of the formulary alternatives: celecoxib, diclofenac, indomethacin, naproxen, or sulindac. Plaque psoriasis: Failure or clinically significant adverse effects to one of the following: acitretin, cyclosporine, methotrexate or phototherapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ENTECAVIR

---

## Products Affected

- BARACLUDE ORAL SOLUTION                      • *entecavir*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Gastroenterologist, Infectious Disease specialist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# ESBRIET

## Products Affected

- ESBRIET ORAL CAPSULE
- ESBRIET ORAL TABLET 267 MG, 801 MG
- *pirfenidone oral tablet 267 mg, 534 mg, 801 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Initial authorization: Diagnosis of idiopathic pulmonary fibrosis confirmed by the presence of usual interstitial pneumonia on high resolution computed tomography (HRCT) and/or surgical lung biopsy. Documentation of liver function tests, documentation of baseline forced vial capacity (FVC) greater than or equal to 50 percent of the predicted value AND documentation of percent predicted diffusing capacity of the lungs for carbon monoxide (%DLCO) greater than or equal to 30 percent.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Pulmonologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ESTROGENS

## Products Affected

- DUAVEE
- *estradiol oral*
- *estradiol transdermal patch weekly*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Postmenopausal osteoporosis prophylaxis: Failure or clinically significant adverse effects all of the formulary alternatives: alendronic acid and risedronate. Vulvar and vaginal atrophy: Failure or clinically significant adverse effects to one of the formulary alternatives: estradiol cream or Premarin Cream.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FENTANYL LOZENGE

## Products Affected

- *fentanyl citrate buccal lozenge on a handle*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Acute, intermittent, or postoperative pain.
<b>Required Medical Information</b>	Documentation of opioid tolerance taking around-the-clock opioid therapy consisting of at least 60mg of oral morphine daily, at least 25mg transdermal fentanyl/hour, at least 30 mg of oral oxycodone daily, at least 8mg oral hydromorphone daily or an equianalgesic dose of another opioid daily for a week or longer for breakthrough pain of cancer. Patients must remain on around-the clock opioids when taking transmucosal immediate release fentanyl.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Pain Specialist, Oncologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FETZIMA

---

## Products Affected

- FETZIMA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FIRAZYR

---

## Products Affected

- *icatibant*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of hereditary angioedema (HAE), must be confirmed by blood testing.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Allergist, Immunologist, Hematologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FIRMAGON

---

## Products Affected

- FIRMAGON KIT W DILUENT SYRINGE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Oncologist, Urologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# GENOTROPIN

## Products Affected

- GENOTROPIN
- GENOTROPIN MINIQUICK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	AGHD(initial): diagnosis confirmed as a result of past diagnosis of childhood-onset GHD, or adult-onset GHD with documentation of hormone deficiency due to hypothalamic-pituitary disease from organic or known causes (eg: damage from surgery, cranial irradiation, head trauma, subarachnoid hemorrhage) and documentation of one growth-hormone stimulant test (eg: insulin tolerance test, arginine/GHRH,glucagon,arginine) to confirm adult GHD w/corresponding peak GH values ([ITT at or below 5mcg/L],[GHRH+ARG at or below 11mcg/L if BMI less than 25kg/m2, at or below 8mcg/L if BMI at or above 25 and below 30kg/m2, or at or below 4mcg/L if BMI at or above 30kg/m2],[glucagon at or below 3mcg/L],[Arg at or below 0.4mcg/L]) or documented deficiency of 3 anterior pituitary hormones (prolactin,ACTH,TSH,FSH/LH) and IFG-1/somatomedinC below age and gender adjusted normal range as provided by physicians lab. AGHD(reauthorization): Documentation of positive experience by the patient.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Endocrinologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# GEODON SOLUTION

---

## Products Affected

- *ziprasidone mesylate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No



# GILENYA

## Products Affected

- *fingolimod*
- GILENYA ORAL CAPSULE 0.5 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Class III or IV heart failure, decompensated heart failure requiring hospitalization, myocardial infarction, stroke, transient ischemic attack or unstable angina within the last 6 months. Concomitant use of Class Ia or Class III anti-arrhythmic drugs. Mobitz type II second-degree or third-degree atrioventricular block, or sick-sinus syndrome unless the patient has a functional pacemaker. QT interval at baseline 500 ms or greater.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	For adults: Failure or clinically significant adverse effects to Aubagio and glatiramer.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# GLATIRAMER

---

## Products Affected

- *glatiramer*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# GLATOPA

---

## Products Affected

- *glatopa*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# GLYBURIDE

## Products Affected

- *glyburide*
- *glyburide-metformin oral tablet 1.25-250 mg, 2.5-500 mg, 5-500 mg*
- *glyburide micronized*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to formulary alternative: glipizide.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# GUANFACINE

## Products Affected

- *guanfacine oral tablet*
- *guanfacine oral tablet extended release 24 hr*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Hypertension: Failure or clinically significant adverse effects to two of the formulary alternatives: benazepril, fosinopril, hydrochlorothiazide, irbesartan, lisinopril, losartan, losartan/hydrochlorothiazide, lisinopril/hydrochlorothiazide, quinapril/hydrochlorothiazide, quinapril, ramipril, or valsartan/hydrochlorothiazide. ADHD: Failure or clinically significant adverse effects to two of the formulary alternatives: amphetamine/dextroamphetamine, dexamethylphenidate, dextroamphetamine, or methylphenidate.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HP ACTHAR

## Products Affected

- ACTHAR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurologist for infantile spasm and exacerbation of multiple sclerosis
Coverage Duration	Multiple sclerosis: 21 days. For other approved indications: 28 days.
Other Criteria	For acute exacerbations of multiple sclerosis, patients must be receiving concurrent immunomodulator therapy, such as Aubagio, glatiramer, or interferon beta 1a. For all other non-neurological indications, failure or clinically significant adverse effects to other first line or standard of care therapies must be submitted.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# HRM ANTIPSYCHOTICS

## Products Affected

- *molindone oral tablet 10 mg, 25 mg, 5 mg*
- *thioridazine*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: olanzapine, risperidone, quetiapine, ziprasidone, or aripiprazole.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HUMIRA

## Products Affected

- HUMIRA PEN
- HUMIRA PEN CROHNS-UC-HS START
- HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML
- HUMIRA(CF)
- HUMIRA(CF) PEN
- HUMIRA(CF) PEN CROHNS-UC-HS
- HUMIRA(CF) PEN PSOR-UV-ADOL HS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Plaque psoriasis: documentation of psoriasis involving 3% of BSA or greater, or affecting crucial body areas such as hands, feet, face or genitals.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Dermatologist, Gastroenterologist, Ophthalmologist, Rheumatologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Rheumatoid Arthritis: Failure or clinically significant adverse effects to one of the formulary alternatives: azathioprine, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine. Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate. Ankylosing spondylitis: Failure or clinically significant adverse effects to one of the formulary alternatives: celecoxib, diclofenac, indomethacin, naproxen, or sulindac. Plaque psoriasis: Failure or clinically significant adverse effects to one of the formulary alternatives: acitretin, cyclosporine, methotrexate or phototherapy. Crohn's disease and Ulcerative colitis: Failure or clinically significant adverse effects to one of the formulary alternatives: budesonide, mesalamine or sulfasalazine.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# HUMIRA PEDIATRIC

## Products Affected

- HUMIRA(CF) PEDI CROHNS STARTER
- HUMIRA(CF) PEN PEDIATRIC UC

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# HUMIRA PSORIASIS

---

## Products Affected

- HUMIRA PEN PSOR-UVEITS-ADOL  
HS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Plaque psoriasis: documentation of psoriasis involving 3% of BSA or greater, or affecting crucial body areas such as hands, feet, face or genitals.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Dermatologist, Rheumatologist, Ophthalmologist, Gastroenterologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# IMIPRAMINE

---

## Products Affected

- *imipramine hcl*
- *imipramine pamoate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# INCRELEX

---

## Products Affected

- INCRELEX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Pediatric patients with malignant neoplasm or history of malignancy. Use for growth promotion in patients with closed epiphyses.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Endocrinologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INDOMETHACIN

---

## Products Affected

- *indomethacin oral capsule*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: celecoxib, diclofenac, ibuprofen, meloxicam, nabumetone, naproxen, or sulindac.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INGREZZA

## Products Affected

- INGREZZA
- INGREZZA INITIATION PACK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Failure or clinically significant adverse effects to the formulary alternative: Austedo. Documentation of baseline Abnormal Involuntary Movement Scale (AIMS) scores. Reauthorization only: Documentation of positive response to medication therapy as evidenced by an improved AIMS score as compared to baseline.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist, Psychiatrist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INTERFERON BETA-1A

## Products Affected

- PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML
- PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML
- REBIF (WITH ALBUMIN)
- REBIF REBIDOSE
- REBIF TITRATION PACK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to all of the formulary alternatives: Aubagio and glatiramer.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INVEGA HAFYERA

---

## Products Affected

- INVEGA HAFYERA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to all of the formulary alternatives: oral paliperidone and Invega Sustenna.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# INVEGA SUSTENNA

---

## Products Affected

- INVEGA SUSTENNA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to the formulary alternative: oral paliperidone.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INVEGA TRINZA

---

## Products Affected

- INVEGA TRINZA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to all of the formulary alternatives: oral paliperidone and Invega Sustenna.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ISOTRETINOIN

## Products Affected

- *amnesteem*
- *claravis*
- *isotretinoin oral capsule 10 mg, 20 mg, 30 mg, 40 mg*
- *myorisan*
- *zenatane*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Dermatologist
<b>Coverage Duration</b>	20 weeks.
<b>Other Criteria</b>	Acne vulgaris: Failure or clinically significant adverse effects to two of the formulary alternatives: benzoyl peroxide/clindamycin topical, benzoyl peroxide/erythromycin topical, clindamycin topical, doxycycline oral, erythromycin topical, minocycline oral, tetracycline oral or tretinoin topical.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ITRACONAZOLE

---

## Products Affected

- *itraconazole oral solution*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# KALYDECO

---

## Products Affected

- KALYDECO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ivacaftor.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Infectious Disease specialist, Pulmonologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# KERENDIA

## Products Affected

- KERENDIA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant use with a strong CYP3A4 inhibitor or diagnosis of adrenal insufficiency
<b>Required Medical Information</b>	Labs within the past 30 days documenting serum potassium level of less than or equal to 5.0 mEq/L, estimated glomerular filtration rate of at least 25 mL/min/1.73m <sup>2</sup> and urine albumin-to-creatinine ratio (UACR) of at least 30 mg/g (2) Receiving concurrent therapy with angiotensin-converting enzyme inhibitor (ACE inhibitor) or angiotensin receptor blocker (ARB) at maximally tolerated labeled dosage, unless contraindicated (3) medical justification that a sodium-glucose cotransport-2 (SGLT2) inhibitor (Jardiance, Invokana, Farxiga, Steglatro) AND a steroidal mineralocorticoid receptor antagonist (spironolactone, eplerenone) have been tried and failed, are contraindicated, or would not be medically appropriate for the patient.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# KORLYM

---

## Products Affected

- KORLYM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Concomitant use of simvastatin, lovastatin and CYP3A substrates with narrow therapeutic ranges (e.g. cyclosporine, fentanyl, sirolimus, etc.). History of unexplained vaginal bleeding or endometrial hyperplasia with atypia or endometrial carcinoma.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LEDIPASVIR-SOFOSBUVIR

## Products Affected

- *ledipasvir-sofosbuvir*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of chronic hepatitis C infection confirmed by a detectable serum hepatitis C virus RNA through quantitative assay. Documentation of genotype. Documentation of the absence or presence of cirrhosis and if compensated or decompensated. Documentation of any previous treatment. Documentation of liver transplant status. Treatment regimen will be approved based on genotype and previous treatment experience as defined by current AASLD guidelines.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Gastroenterologist, Hepatologist, Infectious Disease specialist
<b>Coverage Duration</b>	12 weeks.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to the formulary alternative: sofosbuvir-velpatasvir (generic Epclusa).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# LEUKINE

---

## Products Affected

- LEUKINE INJECTION RECON SOLN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Excessive leukemia myeloid blasts in the bone marrow or peripheral blood equal to or greater than 10%.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Hematologist, Oncologist
<b>Coverage Duration</b>	3 months.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to formulary alternative: Nivestym and Zarxio.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LEUPROLIDE ACETATE

---

## Products Affected

- *leuprolide (3 month)*
- *leuprolide subcutaneous kit*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncologist, Urologist
Coverage Duration	Until the end of calendar year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# LEVALBUTEROL

---

## Products Affected

- *levalbuterol hcl inhalation solution for nebulization 0.31 mg/3 ml, 0.63 mg/3 ml, 1.25 mg/0.5 ml, 1.25 mg/3 ml*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Subject to Part B vs Part D determination. Failure or clinically significant adverse effects to the formulary alternative: albuterol inhalant solution.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LIDOCAINE PATCH

---

## Products Affected

- *lidocaine topical adhesive patch, medicated 5 %*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LINEZOLID

## Products Affected

- *linezolid in dextrose 5%*
- *linezolid oral suspension for reconstitution*
- *linezolid oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Infectious Disease specialist
Coverage Duration	Until the end of calendar year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# LOKELMA

---

## Products Affected

- LOKELMA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of persistent potassium level greater than 5.0 mmol/L at baseline
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Nephrologist, Cardiologist, Endocrinologist, Hematologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to the formulary alternative: sodium polystyrene sulfonate.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LUPRON DEPOT

## Products Affected

- LUPRON DEPOT
- LUPRON DEPOT (3 MONTH)
- LUPRON DEPOT (4 MONTH)
- LUPRON DEPOT (6 MONTH)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Endometriosis: Patient has had surgical ablation to prevent recurrence, or history of failure, contraindication, or intolerance to oral contraceptives.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LYRICA

## Products Affected

- *pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75 mg*
- *pregabalin oral solution*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Postherpetic neuralgia: Failure or clinically significant adverse effects to the formulary alternative: gabapentin. Diabetic neuropathy: Failure or clinically significant adverse effects to all of the formulary alternatives: duloxetine and gabapentin. Fibromyalgia: Failure or clinically significant adverse effects to two of the formulary alternatives: duloxetine, gabapentin or Savella.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# MEGESTROL

## Products Affected

- *megestrol oral suspension 400 mg/10 ml (40 mg/ml)*
- *megestrol oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Cachexia associated with AIDS: Failure or clinically significant adverse effects to all of the formulary alternatives: dronabinol and oxandrolone.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# MEPROBAMATE

## Products Affected

- *meprobamate*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to at least two of the formulary alternatives: buspirone, duloxetine, escitalopram, or venlafaxine.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# METHOCARBAMOL

---

## Products Affected

- *methocarbamol oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Documentation explaining specific benefit established with the medication, and how that benefit outweighs the potential risk
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# METHOXSALEN

## Products Affected

- *methoxsalen*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Dermatologist, Rheumatologist
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to two of the formulary alternatives: calcipotriene, clobetasol, cyclosporine, fluocinonide, methotrexate, or tazarotene.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# METHYLDOPA/HYDROCHLOROTHIAZIDE

## Products Affected

- *methyldopa-hydrochlorothiazide*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: benazepril, fosinopril, hydrochlorothiazide, irbesartan, lisinopril, losartan, losartan/hydrochlorothiazide, lisinopril/hydrochlorothiazide, quinapril/hydrochlorothiazide, quinapril, ramipril, or valsartan/hydrochlorothiazide.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# METYROSINE

---

## Products Affected

- *metyrosine*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Essential hypertension.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# MODAFINIL

---

## Products Affected

- *modafinil*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Narcolepsy: Failure or clinically significant adverse effects to all of the formulary alternatives: dextroamphetamine and methylphenidate.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# NAYZILAM

---

## Products Affected

- NAYZILAM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# NIVESTYM

---

## Products Affected

- NIVESTYM INJECTION

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Hematologist, Infectious Disease specialist, Oncologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NUCALA

---

## Products Affected

- NUCALA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Allergist, Immunologist, Pulmonologist, Rheumatologist, Hematologist, or Otolaryngologist.
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Asthma: Failure or clinically significant adverse effects to two of the formulary alternatives: 1) budesonide, Flovent, Arnuity Ellipta or Qvar and 2) fluticasone-salmeterol, Wixela, or Breo Ellipta.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NUEDEXTA

---

## Products Affected

- NUEDEXTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NUPLAZID

---

## Products Affected

- NUPLAZID

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OCTREOTIDE

---

## Products Affected

- *octreotide acetate injection solution*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OFEV

---

## Products Affected

- OFEV

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Moderate or severe hepatic impairment (Child-Pugh B or C).
<b>Required Medical Information</b>	Initial authorization: Documentation of liver function tests. Reauthorization only: Documentation of positive response to therapy and documentation of liver function tests.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Pulmonologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OLANZAPINE ODT

---

## Products Affected

- *olanzapine oral tablet, disintegrating*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of difficulty or inability to swallow or failure or clinically significant adverse effects to the formulary alternative: oral olanzapine.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OLANZAPINE SOLUTION

---

## Products Affected

- *olanzapine intramuscular*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# OMNITROPE

## Products Affected

- OMNITROPE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	AGHD (initial): diagnosis confirmed as a result of past diagnosis of childhood-onset GHD, or adult-onset GHD with documentation of hormone deficiency due to hypothalamic-pituitary disease from organic or known causes (eg: damage from surgery, cranial irradiation, head trauma, subarachnoid hemorrhage) and documentation of one growth-hormone stimulant test (eg: insulin tolerance test, arginine/GHRH, glucagon, arginine) to confirm adult GHD w/corresponding peak GH values ([ITT at or below 5mcg/L],[GHRH+ARG at or below 11mcg/L if BMI less than 25kg/m2, at or below 8mcg/L if BMI at or above 25 and below 30kg/m2, or at or below 4mcg/L if BMI at or above 30kg/m2],[glucagon at or below 3mcg/L],[Arg at or below 0.4mcg/L]) or documented deficiency of 3 anterior pituitary hormones (prolactin, ACTH, TSH, FSH/LH) and IFG-1/somatomedin C below age and gender adjusted normal range as provided by physicians lab. AGHD (reauthorization): Documentation of positive experience by the patient.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Endocrinologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ORAL ANTIPSYCHOTICS

## Products Affected

- *asenapine maleate*
- CAPLYTA
- FANAPT
- LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG, 80 MG
- *paliperidone oral tablet extended release 24hr 1.5 mg, 3 mg, 6 mg, 9 mg*
- *quetiapine oral tablet extended release 24 hr 150 mg, 200 mg, 300 mg, 400 mg, 50 mg*
- VRAYLAR ORAL CAPSULE
- VRAYLAR ORAL CAPSULE,DOSE PACK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: olanzapine, quetiapine, risperidone, ziprasidone or aripiprazole.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ORENCIA

## Products Affected

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Rheumatologist, transplant specialist
Coverage Duration	Until the end of calendar year.
Other Criteria	Rheumatoid Arthritis: Failure or clinically significant adverse effects to one of the formulary alternatives: azathioprine, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine. Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# ORKAMBI

---

## Products Affected

- ORKAMBI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of homozygous F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Infectious Disease specialist, Pulmonologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OTEZLA

## Products Affected

- OTEZLA
- OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)-20 MG (4)-30 MG (47)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Plaque psoriasis: documentation of psoriasis of greater than 5% BSA or affecting crucial body areas such as hands, feet, face or genitals.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Dermatologist, Rheumatologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate. Plaque psoriasis: Failure or clinically significant adverse effects to one of the formulary alternatives: acitretin, cyclosporine, methotrexate or phototherapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OXANDROLONE

---

## Products Affected

- *oxandrolone*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OXBRYTA

## Products Affected

- OXBRYTA ORAL TABLET 300 MG, 500 MG
- OXBRYTA ORAL TABLET FOR SUSPENSION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of at least 1 episode of vaso-occlusive crisis (VOC) in the past 12 months. Hemoglobin (Hgb) greater than or equal to 5.5 and less than or equal to 10.5 g/dL. Re-authorization: Documentation of positive response to therapy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Hematologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OXERVATE

---

## Products Affected

- OXERVATE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of Stage 2 or 3 neurotrophic keratitis.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Ophthalmologist
<b>Coverage Duration</b>	8 weeks.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# PAH

---

## Products Affected

- *ambrisentan*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Cardiologist, Pulmonologist
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to the formulary alternative: sildenafil or tadalafil. Approve if in combination with tadalafil for treatment naive PAH patients with WHO FC II and III.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# PARATHYROID HORMONE ANALOGS

## Products Affected

- *teriparatide*
- TYMLOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Bone mineral density (BMD) T score of -3.5 or less based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) OR BMD T-score between -2.5 and -3.5 (BMD T-score greater than -3.5 and less than or equal to -2.5) based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) and a history of fractures.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to one of the formulary alternatives: alendronic acid or risedronate. Medical justification required for treatment duration beyond 24 months.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PDE5 INHIBITORS

## Products Affected

- *alyq*
- *sildenafil (pulm.hypertension) oral tablet*
- *tadalafil (pulm. hypertension)*
- TADLIQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with nitrates or PDE5 inhibitors.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Cardiologist, Pulmonologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PEGASYS

---

## Products Affected

- PEGASYS SUBCUTANEOUS SOLUTION
- PEGASYS SUBCUTANEOUS SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Chronic Hepatitis C: Treatment length is determined by FDA labeling or AASLD recommendation
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PEGFILGRASTIM

## Products Affected

- FULPHILA
- UDENYCA
- ZIEXTENZO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematologist, Infectious Disease specialist, Oncologist
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to formulary alternative: Nivestym and Zarxio.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# PHENOBARBITAL

## Products Affected

- *phenobarbital*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: carbamazepine, clonazepam, divalproex, ethosuximide, felbamate, gabapentin, lamotrigine, levetiracetam, lorazepam, oxcarbazepine, phenytoin, tiagabine, topiramate, or zonisamide.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PIMECROLIMUS

## Products Affected

- *pimecrolimus*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to one of the topical formulary alternatives: clobetasol, betamethasone, fluocinolone or fluocinonide and failure or clinically significant adverse effects to the formulary alternative: tacrolimus ointment.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# POSACONAZOLE

## Products Affected

- NOXAFIL ORAL SUSPENSION
- *posaconazole*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to one of the formulary alternatives: fluconazole, itraconazole, or voriconazole.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No



# PREMARIN TABLETS

## Products Affected

- PREMARIN ORAL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Postmenopausal osteoporosis prophylaxis: Failure or clinically significant adverse effects to all of the formulary alternatives: alendronic acid and risedronate. Vulvar and vaginal atrophy: Failure or clinically significant adverse effects to the formulary alternative: estradiol cream. Other indication(s): Failure or clinically significant adverse effects to one of the formulary alternatives: estradiol transdermal patch, estradiol tablet or estropipate.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PREMPRO TABLETS

## Products Affected

- PREMPRO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Postmenopausal osteoporosis prophylaxis: Failure or clinically significant adverse effects to all of the formulary alternatives: alendronic acid, and risedronate. Vulvar and vaginal atrophy: Failure or clinically significant adverse effects to the formulary alternative: estradiol cream. Other indication(s): Failure or clinically significant adverse effects to one of the formulary alternatives: estradiol transdermal patch, estradiol tablet or estropipate.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PREVYMIS

---

## Products Affected

- PREVYMIS ORAL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Infectious Disease specialist, Oncologist, Transplant specialist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PROCRIT

## Products Affected

- PROCRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, 40,000 UNIT/ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Uncontrolled hypertension.
<b>Required Medical Information</b>	For anemia due to chronic kidney disease: Hemoglobin (Hgb) is less than 10g/dL and documentation of transferrin saturation greater than or equal to 20% and ferritin greater than or equal to 100ng/mL. For anemia due to chemotherapy: Hemoglobin (Hgb) is less than 10g/dL. For surgical FDA indications: Hemoglobin (Hgb) is 10g/dL-13g/dL and patient is not a candidate for autologous blood donation and significant blood loss is anticipated from elective, non cardiac, or nonvascular surgery. Zidovudine induced: Hemoglobin (Hgb) is less than 11g/dL. Myelodysplastic syndrome: Hemoglobin (Hgb) is less than 11g/dL and erythropoietin is less than or equal to 500 mU/mL.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Subject to Part B vs Part D determination.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PROLASTIN C

## Products Affected

- PROLASTIN C 1,000 MG/20 ML VL PRICE/ONE MG,SUV
- PROLASTIN-C INTRAVENOUS RECON SOLN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Clinical evidence of emphysema
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year
Other Criteria	Pre-treatment serum levels of alpha-1 antitrypsin (AAT) that is less than 11 micromol/L (80 mg/dl by radial immunodiffusion or 50 mg/dl by nephelometry)
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# PROLIA

## Products Affected

- PROLIA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of bone mineral density (BMD) T-score of -3.5 or less based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) OR BMD T-score between -2.5 and -3.5 (greater than -3.5 and less than or equal to -2.5) based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) and a history of fractures.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to all of the formulary alternatives: alendronic acid and risedronate.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PROMACTA

## Products Affected

- PROMACTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of platelet count. Thrombocytopenia in hepatitis C infection: Documentation of concurrent or planned interferon-based treatment of chronic hepatitis C.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Gastroenterologist, Hematologist, Hepatologist, Infectious Disease specialist, Oncologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Chronic immune (idiopathic) thrombocytopenia: Failure or clinically significant adverse effects to one of the formulary alternatives: dexamethasone, methylprednisolone, prednisolone or prednisone.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PROMETHAZINE

## Products Affected

- *promethazine oral*
- *promethazine rectal suppository 12.5 mg, 25 mg*
- *promethegan rectal suppository 25 mg, 50 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Allergy: Failure or clinically significant adverse effects to one of the formulary alternatives: cetirizine and levocetirizine. Nausea and vomiting: Failure or clinically significant adverse effects to two of the formulary alternatives: chlorpromazine, granisetron, ondansetron, or prochlorperazine.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# PROTRIPTYLINE

---

## Products Affected

- *protriptyline*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# PYRIMETHAMINE

## Products Affected

- *pyrimethamine*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Anemia due to folate deficiency
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Hematologist, HIV specialist, Infectious Disease specialist, Oncologist, Transplant specialist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Primary prophylaxis of toxoplasmic encephalitis: Failure or clinically significant adverse effects to the formulary alternative: trimethoprim/sulfamethoxazole.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# QUININE

---

## Products Affected

- *quinine sulfate*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Prevention or treatment of nocturnal leg cramps.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	10 days.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to one of the formulary alternatives: chloroquine or hydroxychloroquine.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# REPATHA

## Products Affected

- REPATHA PUSHTRONEX
- REPATHA SURECLICK
- REPATHA SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Primary hyperlipidemia: Documentation of current LDL levels above 100mg/dL while taking maximally tolerated statin therapy and ezetimibe therapy, unless intolerant or contraindicated to statin or ezetimibe therapy. Secondary prevention of ASCVD: Documentation of at least one high risk feature: recent ACS (within the past 12 months), history of MI, history of ischemic stroke, or symptomatic peripheral arterial disease (history of claudication with ABI greater than 0.85, or previous revascularization or amputation). Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH): Documentation to confirm diagnosis by genetic testing or by clinical criteria (such as Simon Broome or the Dutch Lipid Clinic Network criteria, or history of untreated LDL-C greater than 180 mg/dL together with xanthoma or cornealis), or evidence of Familial Hypercholesterolemia in first or second-degree relatives.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Cardiologist, Endocrinologist, Lipid specialist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# RETACRIT

## Products Affected

- RETACRIT INJECTION SOLUTION 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, 10,000 UNIT/ML, 2,000 UNIT/ML, 40,000 UNIT/ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Uncontrolled hypertension.
<b>Required Medical Information</b>	For anemia due to chronic kidney disease: Hemoglobin (Hgb) is less than 10g/dL and documentation of transferrin saturation greater than or equal to 20% and ferritin greater than or equal to 100ng/mL. For anemia due to chemotherapy: Hemoglobin (Hgb) is less than 10g/dL. For surgical FDA indications: Hemoglobin (Hgb) is 10g/dL-13g/dL and patient is not a candidate for autologous blood donation and significant blood loss is anticipated from elective, non cardiac, or nonvascular surgery. Zidovudine induced: Hemoglobin (Hgb) is less than 11g/dL. Myelodysplastic syndrome: Hemoglobin (Hgb) is less than 11g/dL and erythropoietin is less than or equal to 500 mU/mL.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Subject to Part B vs Part D determination.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# REXULTI

---

## Products Affected

- REXULTI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Schizophrenia: Failure or clinically significant adverse effects to two of the formulary alternatives: olanzapine, risperidone, quetiapine, ziprasidone or aripiprazole. Depression: Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, mirtazapine, paroxetine, sertraline, or venlafaxine.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# RHOPRESSA

---

## Products Affected

- RHOPRESSA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Medical justification specifying that TWO formulary glaucoma agents from different classes have been tried and failed are contraindicated, or would not be medically appropriate. Drug classes include alpha adrenergic agonists (brimonidine), prostaglandins (latanoprost, travoprost), or beta blockers (timolol, levobunolol).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# RINVOQ

## Products Affected

- RINVOQ ORAL TABLET EXTENDED  
RELEASE 24 HR 15 MG, 30 MG, 45 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Rheumatologist, dermatologist, gastroenterologist
Coverage Duration	Until the end of calendar year.
Other Criteria	Rheumatoid Arthritis: Failure or clinically significant adverse effects to one of the formulary alternatives: azathioprine, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine. Atopic dermatitis: Failure or clinically significant adverse effects to two of the formulary alternatives: cyclosporine, azathioprine, methotrexate.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No



# RISPERDAL CONSTA

---

## Products Affected

- RISPERDAL CONSTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to the formulary alternative: oral risperidone.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# RUFINAMIDE

## Products Affected

- *rufinamide oral suspension*
- *rufinamide oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Failure or clinically significant adverse effects to one of the formulary alternatives: carbamazepine, clonazepam, divalproex, ethosuximide, felbamate, gabapentin, lamotrigine, levetiracetam, lorazepam, oxcarbazepine, phenytoin, tiagabine, topiramate, clobazam or zonisamide. For Rufinamide suspension: Failure or clinically significant adverse effects to one of the formulary alternatives: Rufinamide tablet.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SAPROPTERIN

---

## Products Affected

- *sapropterin*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SECUADO

---

## Products Affected

- SECUADO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: olanzapine, quetiapine, risperidone, ziprasidone or aripiprazole.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SIGNIFOR

---

## Products Affected

- SIGNIFOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SIRTURO

---

## Products Affected

- SIRTURO ORAL TABLET 100 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Infectious Disease specialist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SKYRIZI

## Products Affected

- SKYRIZI SUBCUTANEOUS PEN INJECTOR
- SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML
- SKYRIZI SUBCUTANEOUS SYRINGE KIT
- SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Plaque psoriasis: documentation of psoriasis of greater than 5% BSA or affecting crucial body areas such as hands, feet, face or genitals.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Dermatologist, gastroenterologist, rheumatologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Plaque psoriasis: Failure or clinically significant adverse effects to one of the following: acitretin, cyclosporine, methotrexate or phototherapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SOFOSBUVIR-VELPATASVIR

## Products Affected

- *sofosbuvir-velpatasvir*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of chronic hepatitis C infection confirmed by a detectable serum hepatitis C virus RNA through quantitative assay. Documentation of genotype. Documentation of the absence or presence of cirrhosis and if compensated or decompensated. Documentation of any previous treatment. Documentation of liver transplant status. Treatment regimen will be approved based on genotype and previous treatment experience as defined by current AASLD guidelines.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Gastroenterologist, Hepatologist, Infectious Disease specialist
<b>Coverage Duration</b>	12 weeks.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# SOMAVERT

---

## Products Affected

- SOMAVERT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Endocrinologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to the formulary alternative: octreotide.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SPRITAM

---

## Products Affected

- SPRITAM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to the formulary alternative: levetiracetam oral solution.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# STELARA

## Products Affected

- STELARA SUBCUTANEOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Plaque psoriasis: documentation of psoriasis of greater than 5% BSA or affecting crucial body areas such as hands, feet, face or genitals.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Dermatologist, Gastroenterologist, Rheumatologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate. Plaque psoriasis: Failure or clinically significant adverse effects to one of the formulary alternatives: acitretin, cyclosporine, methotrexate or phototherapy. Crohn's disease and Ulcerative colitis: Failure or clinically significant adverse effects to one of the formulary alternatives: budesonide, mesalamine or sulfasalazine.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SYMDEKO

---

## Products Affected

- SYMDEKO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of homozygous F508del mutation or at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Infectious Disease specialist, Pulmonologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SYMLIN

---

**Products Affected**

- SYMLINPEN 120
- SYMLINPEN 60

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Confirmed gastroparesis.
<b>Required Medical Information</b>	Documentation of a history of HbA1C scores of 7% or higher after at least 3 months of optimal therapy with insulin.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SYMPAZAN

---

## Products Affected

- SYMPAZAN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of difficulty or inability to swallow.
Age Restrictions	
Prescriber Restrictions	Neurologist
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to two of the formulary alternatives: carbamazepine, clonazepam, divalproex, ethosuximide, felbamate, gabapentin, lamotrigine, levetiracetam, lorazepam, oxcarbazepine, phenytoin, tiagabine, topiramate, valproic acid or zonisamide.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# SYNAREL

---

## Products Affected

- SYNAREL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TACROLIMUS OINTMENT

## Products Affected

- *tacrolimus topical*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to two of the topical formulary alternatives: clobetasol, betamethasone, fluocinolone, or fluocinonide.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No



# TAKHZYRO

---

## Products Affected

- TAKHZYRO SUBCUTANEOUS SOLUTION

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of hereditary angioedema (HAE), must be confirmed by blood testing.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Allergist, Immunologist, Hematologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TALTZ

## Products Affected

- TALTZ AUTOINJECTOR
- TALTZ SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Plaque psoriasis: documentation of psoriasis of greater than 5% BSA or affecting crucial body areas such as hands, feet, face or genitals.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Dermatologist, Rheumatologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate. Ankylosing spondylitis: Failure or clinically significant adverse effects to one of the formulary alternatives: celecoxib, diclofenac, indomethacin, naproxen, or sulindac. Plaque psoriasis: Failure or clinically significant adverse effects to one of the formulary alternatives: acitretin, cyclosporine, methotrexate or phototherapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TARGRETIN

## Products Affected

- *bexarotene*
- TARGRETIN TOPICAL

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Dermatologist, Oncologist
Coverage Duration	Until the end of calendar year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# TAZORAC

## Products Affected

- *tazarotene topical cream*
- *tazarotene topical gel*
- TAZORAC TOPICAL CREAM 0.05 %
- TAZORAC TOPICAL GEL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Plaque psoriasis: Failure or clinically significant adverse effects to one of the topical formulary alternatives: calcipotriene, clobetasol or fluocinonide. Acne vulgaris: Failure or clinically significant adverse effects to two of the formulary alternatives: benzoyl peroxide/clindamycin topical, benzoyl peroxide/erythromycin topical, clindamycin topical, doxycycline oral, erythromycin topical, minocycline oral, tetracycline oral or tretinoin topical.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TECFIDERA

---

## Products Affected

- *dimethyl fumarate*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to all of the formulary alternatives: Aubagio and glatiramer.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TESTOSTERONE

## Products Affected

- *methyltestosterone oral capsule*
- *testosterone cypionate intramuscular oil 100 mg/ml, 200 mg/ml*
- *testosterone enanthate*
- *testosterone transdermal gel in metered-dose pump*
- *testosterone transdermal gel in packet*
- *testosterone transdermal solution in metered pump w/app*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented pretreatment serum testosterone levels less than the laboratory's lower reference limit within the recent 3 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TESTOSTERONE PUMP

## Products Affected

- *testosterone transdermal gel in metered-dose pump*
- *testosterone transdermal gel in packet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented pretreatment serum testosterone levels less than the laboratory's lower reference limit within the recent 3 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: testosterone cypionate, testosterone enanthate or testosterone transdermal gel or solution.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TETRABENAZINE

---

## Products Affected

- *tetrabenazine*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Concurrent use with an MAOI. Untreated or inadequately-treated depression, or current suicidality.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# TIGECYCLINE

---

## Products Affected

- *tigecycline*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Infectious Disease specialist
Coverage Duration	Until the end of calendar year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# TOBI PODHALER

---

## Products Affected

- TOBI PODHALER INHALATION CAPSULE, W/INHALATION DEVICE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Infectious Disease specialist, Pulmonologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TOBRAMYCIN SOLUTION

---

## Products Affected

- *tobramycin in 0.225 % nacl*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Infectious Disease specialist, Pulmonologist
Coverage Duration	Until the end of calendar year.
Other Criteria	Subject to Part B vs Part D determination.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# TOLCAPONE

---

## Products Affected

- *tolcapone*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of concurrent use with levodopa and carbidopa.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: amantadine, bromocriptine, carbidopa/levodopa, entacapone, pramipexole, ropinirole, or selegiline.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TRIENTINE

---

## Products Affected

- *trientine*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Biliary cirrhosis, rheumatoid arthritis.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to the formulary alternative: penicillamine.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TRIHXYPHENIDYL

## Products Affected

- *trihexyphenidyl*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Narrow angle glaucoma.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Parkinsonism: Failure or clinically significant adverse effects to one of the formulary alternatives: amantadine, bromocriptine, carbidopa/levodopa, entacapone, pramipexole, ropinirole, or selegiline. Medication-induced movement disorder - extrapyramidal disease: Failure or clinically significant adverse effects to the formulary alternative: amantadine.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TRIMIPRAMINE

---

## Products Affected

- *trimipramine*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TRINTELLIX

---

## Products Affected

- TRINTELLIX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# UBRELVY

## Products Affected

- UBRELVY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Medical justification specifying that TWO formulary anti-migraine drugs from different classes have been tried and failed are contraindicated, or would not be medically appropriate. Classes include: (1) Analgesics- aspirin, naproxen, ibuprofen, diclofenac, celecoxib, indomethacin, nabumetone, and (2) Triptans- sumatriptan, rizatriptan/rizatriptan ODT
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist, Pain Specialist, Headache Specialist
<b>Coverage Duration</b>	Until the end of calendar year
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VALCHLOR

---

## Products Affected

- VALCHLOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Dermatologist, Oncologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VANCOMYCIN CAPSULE

---

## Products Affected

- *vancomycin oral capsule 125 mg, 250 mg*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	C diff diarrhea: Reauthorization: Documentation of C. Difficile positive stool
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VASCEPA

## Products Affected

- *icosapent ethyl oral capsule 0.5 gram, 1 gram*
- VASCEPA ORAL CAPSULE 0.5 GRAM

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Reduction of risk for myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization: Documentation of maximally tolerated statin therapy, unless intolerant or contraindicated, with elevated triglycerides greater than or equal to 150 mg/dL and with either established cardiovascular disease or diabetes mellitus with two or more additional risk factors for cardiovascular disease. Severe hypertriglyceridemia: Documentation of elevated triglycerides greater than or equal to 500 mg/dL.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Lipidologist, Cardiologist, Endocrinologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to the formulary alternative: omega-3 acid ethyl esters.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VEMLIDY

---

## Products Affected

- VEMLIDY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Hepatologist, Gastroenterologist, Infectious Disease specialist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VIBERZI

---

## Products Affected

- VIBERZI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	History of gallbladder removal.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to the all of the formulary alternatives: dicyclomine and loperamide.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VIGABATRIN

## Products Affected

- *vigabatrín oral powder in packet*
- *vigadrone*
- *vigabatrín oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Refractory Complex Partial Seizures only: Failure or clinically significant adverse effects to two of the formulary alternatives: carbamazepine, clonazepam, divalproex, ethosuximide, felbamate, gabapentin, lamotrigine, levetiracetam, lorazepam, oxcarbazepine, phenytoin, tiagabine, topiramate, or zonisamide
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No





# VORICONAZOLE

---

## Products Affected

- *voriconazole intravenous*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XATMEP

---

## Products Affected

- XATMEP

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Oncologist, Pediatrician, Rheumatologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Subject to Part B vs Part D determination.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XELJANZ

## Products Affected

- XELJANZ ORAL SOLUTION
- XELJANZ ORAL TABLET
- XELJANZ XR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Gastroenterologist, Rheumatologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Rheumatoid Arthritis: Failure or clinically significant adverse effects to one of the formulary alternatives: azathioprine, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine. Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate. Ulcerative colitis: Failure or clinically significant adverse effects to formulary alternative: Humira.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XGEVA

---

## Products Affected

- XGEVA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Oncologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XIFAXAN

---

## Products Affected

- XIFAXAN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Hepatic encephalopathy: Failure or clinically significant adverse effects to the formulary alternative: lactulose. Irritable bowel syndrome with diarrhea: Failure or clinically significant adverse effects to all of the formulary alternative: loperamide. Traveler's diarrhea: Failure or clinically significant adverse effects to one of the formulary alternatives: ciprofloxacin or levofloxacin.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# XOLAIR

---

## Products Affected

- XOLAIR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Asthma (Initial): Forced expiratory volume in one second or peak expiratory flow less than or equal to 80% of predicted level, or measures of asthma control indicate uncontrolled asthma (eg, Asthma Control Test [ACT] score 19 or less). Baseline (pre-Xolair treatment) serum total IgE level greater than or equal to 30 IU/mL. Positive skin test or in vitro reactivity to a perennial aeroallergen.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Allergist, Dermatologist, Immunologist, Pulmonologist, Otolaryngologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XYREM

## Products Affected

- XYREM

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Daytime excessive sleepiness in patients with narcolepsy: Failure or clinically significant adverse effects to two of the formulary alternatives: dextroamphetamine, methylphenidate, and modafinil.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ZARXIO

---

## Products Affected

- ZARXIO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Hematologist, Infectious Disease specialist, Oncologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# ZEPATIER

## Products Affected

- ZEPATIER

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of chronic hepatitis C infection confirmed by a detectable serum hepatitis C virus RNA through quantitative assay. Documentation of genotype. Documentation of the absence or presence of cirrhosis and if compensated or decompensated. Documentation of any previous treatment. Documentation of liver transplant status. Treatment regimen will be approved based on genotype and previous treatment experience as defined by current AASLD guidelines. For genotype 1a: Documentation for NS5A polymorphism testing.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Gastroenterologist, Hepatologist, Infectious Disease specialist
<b>Coverage Duration</b>	12 to 16 weeks dependent on genotype and polymorphism, cirrhosis, or previous treatment.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ZYPREXA RELPREVV

---

## Products Affected

- ZYPREXA RELPREVV  
INTRAMUSCULAR SUSPENSION FOR  
RECONSTITUTION 210 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented history of receiving oral olanzapine without any clinically significant side effects.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: Invega Sustenna, Invega Trinza or Risperdal Consta.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

## INDEX

### A

ABELCET.....	1
ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 300 MG, 400 MG .....	2
ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING.....	2
abiraterone oral tablet 250 mg, 500 mg ...	15, 16, 17
acitretin .....	3
ACTHAR .....	62
ACTIMMUNE.....	4
adefovir .....	5
AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 2 MG .....	15, 16, 17
AIMOVIG AUTOINJECTOR.....	7
ALECENSA.....	15, 16, 17
alosectron.....	8
ALUNBRIG.....	15, 16, 17
alyq.....	115
AMBISOME.....	9
ambrisentan .....	113
amitriptyline.....	10
amnestem.....	75
amoxapine .....	11
amphotericin b .....	12
APOKYN.....	18
apomorphine .....	18
aprepitant.....	19
APTIOM ORAL TABLET 200 MG, 400 MG, 600 MG, 800 MG .....	13
ARCALYST .....	20
aripiprazole oral solution .....	21
aripiprazole oral tablet,disintegrating .....	21
armodafinil.....	22
asenapine maleate .....	106
atovaquone .....	23
AUBAGIO .....	24
AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG .....	25
AUVELITY .....	26

AYVAKIT ORAL TABLET 100 MG, 200  
MG, 25 MG, 300 MG, 50 MG.. 15, 16, 17

### B

BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG.....	15, 16, 17
BARACLUDGE ORAL SOLUTION .....	48
BESREMI .....	15, 16, 17
bexarotene .....	155
BOSULIF.....	15, 16, 17
BRAFTOVI ORAL CAPSULE 75 MG ..	15, 16, 17

BRIVIACT ORAL SOLUTION..... 13

BRIVIACT ORAL TABLET 10 MG, 100  
MG, 25 MG, 50 MG, 75 MG..... 13

BRUKINSA ..... 15, 16, 17 |

### C

CABOMETYX .....	15, 16, 17
CALQUENCE .....	15, 16, 17
CALQUENCE (ACALABRUTINIB MAL) .....	15, 16, 17
CAPLYTA .....	106
CAPRELSA .....	15, 16, 17
casprofungin.....	27
claravis .....	75
clobazam oral suspension .....	14
clobazam oral tablet .....	14
clomipramine .....	28
clozapine oral tablet,disintegrating 100 mg, 12.5 mg, 150 mg, 200 mg, 25 mg .....	29
COMETRIQ.....	15, 16, 17
COPIKTRA.....	15, 16, 17
CORLANOR ORAL SOLUTION.....	31
CORLANOR ORAL TABLET .....	31
COSENTYX (2 SYRINGES).....	32
COSENTYX PEN (2 PENS) .....	32
COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML.....	32
COTELLIC .....	15, 16, 17
cyclobenzaprine oral tablet 10 mg, 5 mg..	33

### D

dalfampridine .....	34
DALIRESP .....	35
DAURISMO ORAL TABLET 100 MG, 25 MG .....	15, 16, 17

deferasirox oral tablet, dispersible .....	36	FINTEPLA.....	14
desipramine .....	37	FIRMAGON KIT W DILUENT SYRINGE	
dexmethylphenidate oral tablet .....	6	.....	54
DIACOMIT.....	14	FOTIVDA.....	15, 16, 17
diazepam intensol.....	38	FULPHILA .....	117
diazepam oral solution 5 mg/5 ml (1 mg/ml)		FYCOMPA ORAL SUSPENSION .....	13
.....	38	FYCOMPA ORAL TABLET.....	13
dimethyl fumarate .....	39, 157	<b>G</b>	
disopyramide phosphate oral capsule .....	40	GAVRETO .....	15, 16, 17
doxepin oral capsule .....	41	GENOTROPIN .....	55
doxepin oral concentrate.....	41	GENOTROPIN MINIQUICK .....	55
DRIZALMA SPRINKLE .....	42	GILENYA ORAL CAPSULE 0.5 MG.....	57
dronabinol .....	43	GILOTRIF .....	15, 16, 17
droxidopa .....	44	glatiramer .....	58
DUAVEE .....	50	glatopa.....	59
<b>E</b>		GLEOSTINE.....	15, 16, 17
ELIGARD.....	45	glyburide .....	60
ELIGARD (3 MONTH).....	45	glyburide micronized .....	60
ELIGARD (4 MONTH).....	45	glyburide-metformin oral tablet 1.25-250	
ELIGARD (6 MONTH).....	45	mg, 2.5-500 mg, 5-500 mg.....	60
EMSAM.....	46	guanfacine oral tablet .....	61
ENBREL.....	47	guanfacine oral tablet extended release 24 hr	
ENBREL MINI.....	47	.....	61
ENBREL SURECLICK.....	47	<b>H</b>	
entecavir .....	48	HUMIRA PEN.....	64
EPIDIOLEX.....	13	HUMIRA PEN CROHNS-UC-HS START	
ERIVEDGE.....	15, 16, 17	.....	64
ERLEADA .....	15, 16, 17	HUMIRA PEN PSOR-UVEITS-ADOL HS	
erlotinib oral tablet 100 mg, 150 mg, 25 mg		.....	66
.....	15, 16, 17	HUMIRA SUBCUTANEOUS SYRINGE	
ESBRIET ORAL CAPSULE.....	49	KIT 40 MG/0.8 ML .....	64
ESBRIET ORAL TABLET 267 MG, 801		HUMIRA(CF).....	64
MG .....	49	HUMIRA(CF) PEDI CROHNS STARTER	
estradiol oral.....	50	.....	65
estradiol transdermal patch weekly.....	50	HUMIRA(CF) PEN .....	64
everolimus (antineoplastic) oral tablet 15, 16,		HUMIRA(CF) PEN CROHNS-UC-HS....	64
17		HUMIRA(CF) PEN PEDIATRIC UC.....	65
everolimus (antineoplastic) oral tablet for		HUMIRA(CF) PEN PSOR-UV-ADOL HS	
suspension 3 mg, 5 mg.....	15, 16, 17	.....	64
EXKIVITY .....	15, 16, 17	<b>I</b>	
<b>F</b>		IBRANCE.....	15, 16, 17
FANAPT .....	106	icatibant.....	53
fentanyl citrate buccal lozenge on a handle		ICLUSIG ORAL TABLET 10 MG, 15 MG,	
.....	51	30 MG, 45 MG.....	15, 16, 17
FETZIMA .....	52	icosapent ethyl oral capsule 0.5 gram, 1	
fingolimod.....	57	gram .....	172

IDHIFA ..... 15, 16, 17  
 imatinib oral tablet 100 mg, 400 mg.. 15, 16, 17  
 IMBRUVICA ORAL CAPSULE 140 MG, 70 MG ..... 15, 16, 17  
 IMBRUVICA ORAL SUSPENSION 15, 16, 17  
 IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG, 560 MG ..... 15, 16, 17  
 imipramine hcl ..... 67  
 imipramine pamoate..... 67  
 INCRELEX..... 68  
 indomethacin oral capsule..... 69  
 INGREZZA..... 70  
 INGREZZA INITIATION PACK ..... 70  
 INLYTA ORAL TABLET 1 MG, 5 MG. 15, 16, 17  
 INQOVI ..... 15, 16, 17  
 INREBIC..... 15, 16, 17  
 INVEGA HAFYERA ..... 72  
 INVEGA SUSTENNA ..... 73  
 INVEGA TRINZA..... 74  
 IRESSA..... 15, 16, 17  
 isotretinoin oral capsule 10 mg, 20 mg, 30 mg, 40 mg ..... 75  
 itraconazole oral solution ..... 76

**J**  
 JAKAFI..... 15, 16, 17

**K**  
 KALYDECO..... 77  
 KERENDIA ..... 78  
 KISQALI FEMARA CO-PACK .. 15, 16, 17  
 KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3)... 15, 16, 17  
 KORLYM ..... 79  
 KOSELUGO ORAL CAPSULE 10 MG, 25 MG ..... 15, 16, 17  
 KRAZATI..... 15, 16, 17

**L**  
 lapatinib..... 15, 16, 17  
 LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG, 80 MG..... 106  
 ledipasvir-sofosbuvir..... 80  
 lenalidomide..... 15, 16, 17

LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1), 12 MG/DAY (4 MG X 3), 14 MG/DAY(10 MG X 1-4 MG X 1), 18 MG/DAY (10 MG X 1-4 MG X2), 20 MG/DAY (10 MG X 2), 24 MG/DAY(10 MG X 2-4 MG X 1), 4 MG, 8 MG/DAY (4 MG X 2)..... 15, 16, 17  
 LEUKINE INJECTION RECON SOLN.. 81  
 leuprolide (3 month) ..... 82  
 leuprolide subcutaneous kit..... 82  
 levalbuterol hcl inhalation solution for nebulization 0.31 mg/3 ml, 0.63 mg/3 ml, 1.25 mg/0.5 ml, 1.25 mg/3 ml..... 83  
 lidocaine topical adhesive patch,medicated 5 % ..... 84  
 linezolid in dextrose 5%..... 85  
 linezolid oral suspension for reconstitution ..... 85  
 linezolid oral tablet ..... 85  
 LOKELMA ..... 86  
 LONSURF ..... 15, 16, 17  
 LORBRENA ORAL TABLET 100 MG, 25 MG ..... 15, 16, 17  
 LUMAKRAS ..... 15, 16, 17  
 LUPRON DEPOT..... 87  
 LUPRON DEPOT (3 MONTH) ..... 87  
 LUPRON DEPOT (4 MONTH) ..... 87  
 LUPRON DEPOT (6 MONTH) ..... 87  
 LYNPARZA ..... 15, 16, 17  
 LYTGABI..... 15, 16, 17

**M**  
 MATULANE ..... 15, 16, 17  
 megestrol oral suspension 400 mg/10 ml (40 mg/ml)..... 89  
 megestrol oral tablet..... 89  
 MEKINIST ORAL TABLET 0.5 MG, 2 MG ..... 15, 16, 17  
 MEKTOVI ..... 15, 16, 17  
 meprobamate..... 90  
 methocarbamol oral ..... 91  
 methoxsalen ..... 92  
 methyl dopa-hydrochlorothiazide ..... 93  
 methylphenidate hcl oral capsule, er biphasic 30-70..... 6  
 methylphenidate hcl oral capsule,er biphasic 50-50 ..... 6

methylphenidate hcl oral solution..... 6  
 methylphenidate hcl oral tablet..... 6  
 methylphenidate hcl oral tablet extended  
 release ..... 6  
 methyltestosterone oral capsule ..... 158  
 metyrosine..... 94  
 modafinil..... 95  
 molindone oral tablet 10 mg, 25 mg, 5 mg 63  
 MOVANTIK..... 30  
 myorisan..... 75  
**N**  
 NAYZILAM ..... 96  
 NERLYNX ..... 15, 16, 17  
 NEXAVAR..... 15, 16, 17  
 NINLARO..... 15, 16, 17  
 NIVESTYM INJECTION ..... 97  
 NOXAFIL ORAL SUSPENSION ..... 120  
 NUBEQA ..... 15, 16, 17  
 NUCALA..... 98  
 NUEDEXTA..... 99  
 NUPLAZID..... 100  
**O**  
 octreotide acetate injection solution..... 101  
 ODOMZO ..... 15, 16, 17  
 OFEV ..... 102  
 olanzapine intramuscular ..... 104  
 olanzapine oral tablet, disintegrating ..... 103  
 OMNITROPE ..... 105  
 ONUREG ..... 15, 16, 17  
 ORENCIA CLICKJECT..... 107  
 ORENCIA SUBCUTANEOUS SYRINGE  
 125 MG/ML, 50 MG/0.4 ML, 87.5  
 MG/0.7 ML ..... 107  
 ORGOVYX..... 15, 16, 17  
 ORKAMBI..... 108  
 OTEZLA ..... 109  
 OTEZLA STARTER ORAL  
 TABLETS, DOSE PACK 10 MG (4)-20  
 MG (4)-30 MG (47) ..... 109  
 oxandrolone..... 110  
 OXBRYTA ORAL TABLET 300 MG, 500  
 MG ..... 111  
 OXBRYTA ORAL TABLET FOR  
 SUSPENSION ..... 111  
 OXERVATE..... 112

**P**  
 paliperidone oral tablet extended release  
 24hr 1.5 mg, 3 mg, 6 mg, 9 mg..... 106  
 PANRETIN..... 15, 16, 17  
 PEGASYS SUBCUTANEOUS SOLUTION  
 ..... 116  
 PEGASYS SUBCUTANEOUS SYRINGE  
 ..... 116  
 PEMAZYRE..... 16, 17  
 phenobarbital..... 118  
 pimecrolimus..... 119  
 PIQRAY ORAL TABLET 200 MG/DAY  
 (200 MG X 1), 250 MG/DAY (200 MG  
 X1-50 MG X1), 300 MG/DAY (150 MG  
 X 2) ..... 16, 17  
 pirfenidone oral tablet 267 mg, 534 mg, 801  
 mg ..... 49  
 PLEGRIDY SUBCUTANEOUS PEN  
 INJECTOR 125 MCG/0.5 ML ..... 71  
 PLEGRIDY SUBCUTANEOUS SYRINGE  
 125 MCG/0.5 ML ..... 71  
 POMALYST ..... 16, 17  
 posaconazole ..... 120  
 pregabalin oral capsule 100 mg, 150 mg,  
 200 mg, 225 mg, 25 mg, 300 mg, 50 mg,  
 75 mg ..... 88  
 pregabalin oral solution..... 88  
 PREMARIN ORAL ..... 121  
 PREMPRO..... 122  
 PREVYMIS ORAL ..... 123  
 PROCREDIT INJECTION SOLUTION 10,000  
 UNIT/ML, 2,000 UNIT/ML, 20,000  
 UNIT/ML, 3,000 UNIT/ML, 4,000  
 UNIT/ML, 40,000 UNIT/ML ..... 124  
 PROLASTIN C 1,000 MG/20 ML VL  
 PRICE/ONE MG, SUV ..... 125  
 PROLASTIN-C INTRAVENOUS RECON  
 SOLN ..... 125  
 PROLIA ..... 126  
 PROMACTA ..... 127  
 promethazine oral..... 128  
 promethazine rectal suppository 12.5 mg, 25  
 mg ..... 128  
 promethazine rectal suppository 25 mg, 50  
 mg ..... 128  
 protriptyline..... 129

PURIXAN..... 16, 17  
pyrimethamine ..... 130  
**Q**  
QINLOCK..... 16, 17  
quetiapine oral tablet extended release 24 hr  
150 mg, 200 mg, 300 mg, 400 mg, 50 mg  
..... 106  
quinine sulfate..... 131  
**R**  
REBIF (WITH ALBUMIN) ..... 71  
REBIF REBIDOSE..... 71  
REBIF TITRATION PACK ..... 71  
REPATHA PUSHTRONEX..... 132  
REPATHA SURECLICK..... 132  
REPATHA SYRINGE..... 132  
RETACRIT INJECTION SOLUTION  
10,000 UNIT/ML, 2,000 UNIT/ML,  
20,000 UNIT/ML, 3,000 UNIT/ML,  
4,000 UNIT/ML, 40,000 UNIT/ML ... 133  
RETEVMO ORAL CAPSULE 40 MG, 80  
MG ..... 16, 17  
REVLIMID ..... 16, 17  
REXULTI ..... 134  
REZLIDHIA ..... 16, 17  
RHOPRESSA ..... 135  
RINVOQ ORAL TABLET EXTENDED  
RELEASE 24 HR 15 MG, 30 MG, 45  
MG ..... 136  
RISPERDAL CONSTA..... 137  
roflumilast..... 35  
ROZLYTREK ORAL CAPSULE 100 MG,  
200 MG ..... 16, 17  
RUBRACA ..... 16, 17  
rufinamide oral suspension ..... 138  
rufinamide oral tablet..... 138  
RYDAPT..... 16, 17  
**S**  
sapropterin..... 139  
SCEMBLIX ORAL TABLET 20 MG, 40  
MG ..... 16, 17  
SECUADO..... 140  
SIGNIFOR ..... 141  
sildenafil (pulm.hypertension) oral tablet 115  
SIRTURO ORAL TABLET 100 MG..... 142  
SKYRIZI SUBCUTANEOUS PEN  
INJECTOR..... 143

SKYRIZI SUBCUTANEOUS SYRINGE  
150 MG/ML ..... 143  
SKYRIZI SUBCUTANEOUS SYRINGE  
KIT ..... 143  
SKYRIZI SUBCUTANEOUS WEARABLE  
INJECTOR..... 143  
sofosbuvir-velpatasvir..... 144  
SOMAVERT..... 145  
sorafenib..... 16, 17  
SPRITAM ..... 146  
SPRYCEL ORAL TABLET 100 MG, 140  
MG, 20 MG, 50 MG, 70 MG, 80 MG . 16,  
17  
STELARA SUBCUTANEOUS..... 147  
STIVARGA ..... 16, 17  
sunitinib..... 16, 17  
SUTENT ..... 16, 17  
SYMDEKO..... 148  
SYMLINPEN 120..... 149  
SYMLINPEN 60..... 149  
SYMPAZAN..... 150  
SYNAREL ..... 151  
SYNRIBO ..... 16, 17  
**T**  
TABLOID..... 16, 17  
TABRECTA ..... 16, 17  
tacrolimus topical..... 152  
tadalafil (pulm. hypertension)..... 115  
TADLIQ..... 115  
TAFINLAR..... 16, 17  
TAGRISSO ..... 16, 17  
TAKHZYRO SUBCUTANEOUS  
SOLUTION..... 153  
TALTZ AUTOINJECTOR..... 154  
TALTZ SYRINGE..... 154  
TALZENNA ORAL CAPSULE 0.25 MG,  
0.5 MG, 0.75 MG, 1 MG ..... 16, 17  
TARGRETIN TOPICAL ..... 155  
TASIGNA ..... 16, 17  
tazarotene topical cream ..... 156  
tazarotene topical gel ..... 156  
TAZORAC TOPICAL CREAM 0.05 % 156  
TAZORAC TOPICAL GEL ..... 156  
TAZVERIK..... 16, 17  
TEPMETKO ..... 16, 17  
teriparatide ..... 114

testosterone cypionate intramuscular oil 100 mg/ml, 200 mg/ml.....	158	VERZENIO.....	16, 17
testosterone enanthate .....	158	VIBERZI.....	174
testosterone transdermal gel in metered-dose pump .....	158, 159	vigabatrin oral powder in packet.....	175
testosterone transdermal gel in packet ...	158, 159	vigabatrin oral tablet .....	175
testosterone transdermal solution in metered pump w/app.....	158	vigadrone.....	175
tetrabenazine .....	160	VIIBRYD ORAL TABLET.....	176
THALOMID .....	16, 17	VIIBRYD ORAL TABLETS,DOSE PACK 10 MG (7)- 20 MG (23).....	176
thioridazine .....	63	vilazodone .....	176
TIBSOVO .....	16, 17	VIMPAT ORAL TABLET.....	14
tigecycline.....	161	VITRAKVI ORAL CAPSULE 100 MG, 25 MG .....	16, 17
TOBI PODHALER INHALATION CAPSULE, W/INHALATION DEVICE .....	162	VITRAKVI ORAL SOLUTION .....	16, 17
tobramycin in 0.225 % nacl .....	163	VIZIMPRO .....	16, 17
tolcapone.....	164	VONJO .....	16, 17
trientine .....	165	voriconazole intravenous .....	177
trihexyphenidyl .....	166	VOTRIENT.....	16, 17
trimipramine.....	167	VRAYLAR ORAL CAPSULE.....	106
TRINTELLIX .....	168	VRAYLAR ORAL CAPSULE,DOSE PACK.....	106
TRUSELTIQ ORAL CAPSULE 100 MG/DAY (100 MG X 1), 125 MG/DAY(100 MG X1-25MG X1), 50 MG/DAY (25 MG X 2), 75 MG/DAY (25 MG X 3).....	16, 17	<b>W</b>	
TUKYSA ORAL TABLET 150 MG, 50 MG .....	16, 17	WELIREG.....	16, 17
TURALIO ORAL CAPSULE 125 MG, 200 MG .....	16, 17	<b>X</b>	
TYMLOS .....	114	XALKORI.....	16, 17
<b>U</b>		XATMEP .....	178
UBRELVY.....	169	XELJANZ ORAL SOLUTION .....	179
UDENYCA.....	117	XELJANZ ORAL TABLET.....	179
<b>V</b>		XELJANZ XR .....	179
VALCHLOR.....	170	XERMELO .....	16, 17
vancomycin oral capsule 125 mg, 250 mg .....	171	XGEVA.....	180
VASCEPA ORAL CAPSULE 0.5 GRAM .....	172	XIFAXAN.....	181
VEMLIDY .....	173	XOLAIR .....	182
VENCLEXTA.....	16, 17	XOSPATA .....	16, 17
VENCLEXTA STARTING PACK ....	16, 17	XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (40 MG X 1), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80MG TWICE WEEK (160 MG/WEEK) .....	16, 17
VERSACLOZ.....	29	XTANDI.....	16, 17
		XYREM .....	183
		<b>Y</b>	
		YONSA.....	16, 17
		<b>Z</b>	
		ZARXIO .....	184



ZEJULA ..... 16, 17  
ZELBORAF ..... 16, 17  
zenatane ..... 75  
ZEPATIER ..... 185  
ZIEXTENZO ..... 117  
ziprasidone mesylate ..... 56

ZOLINZA ..... 16, 17  
ZYDELIG ..... 16, 17  
ZYKADIA ..... 16, 17  
ZYPREXA RELPREVV  
INTRAMUSCULAR SUSPENSION  
FOR RECONSTITUTION 210 MG... 186